It’s a rather sad fact of medical life that in 70 years of treatment for polymyalgia rheumatica, options have moved on hardly at all. Prednisolone remains the standard treatment, although its adverse side-effects are well-documented, and feared by many patients. However, prednisolone is very effective in the majority of cases, and it is very cheap. For these reasons, there has been very little incentive for pharmaceutical companies to look for alternatives.
